Novogen Limited (ADR)  

(Public, NASDAQ:NVGN)   Watch this stock  
Find more results for NVGN
-0.13 (-5.31%)
Nov 30 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.30 - 2.45
52 week 1.52 - 9.50
Open 2.45
Vol / Avg. 51,752.00/71,075.00
Mkt cap 39.83M
P/E     -
Div/yield     -
EPS -0.52
Shares 168.56M
Beta -0.05
Inst. own 0%
Feb 22, 2016
Q1 2015 Novogen Ltd Earnings Release (Estimated) Add to calendar
Nov 11, 2015
Novogen Ltd Annual Shareholders Meeting
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2015
Net profit margin -5820.37% -8185.13%
Operating margin -6676.74% -10855.79%
EBITD margin - -10211.65%
Return on average assets -34.66% -28.76%
Return on average equity -37.05% -30.92%
Employees 12 -
CDP Score - -


L 1 16 - 20 Edgeworth David Ave
+61-2-98780088 (Phone)
+61-2-94760388 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Novogen Limited (Novogen) is a drug discovery company. The Company is primarily engaged in pharmaceutical research and development. The Company's operations include CanTx Inc., its United States-based joint venture company with Yale University. Novogen has two drug technology platforms (the superbenzopyrans (SBPs) and anti-tropomyosins (ATMs)) yielding drug candidates that have application across a range of degenerative diseases. The Company's product candidates include Cantrixil, Anisina and Trilexium (TRXE-009). The Company's target indication for Cantrixil is ovarian cancer and Diffuse Intrinsic Pontine Glioma (DIPG) for Trilexium. The initial target pediatric indication for Anisina is neuroblastoma. The Company primarily focuses on four therapeutic areas: oncology, degenerative diseases, regenerative medicine and autoimmune diseases. It is engaged in pre-clinical steps to undergo a Phase I study for Cantrixil, Anisina and Trilexium.

Officers and directors

Ian Maurice Phillips Interim Chairman of the Board
Bio & Compensation  - Reuters
Iain Ross Acting Chief Executive Officer, Director
Bio & Compensation  - Reuters
Cristyn Humphreys Chief Operating Officer - Administration and Finance
Bio & Compensation  - Reuters
David Brown Chief Scientific Officer
Bio & Compensation  - Reuters
Andrew Heaton Vice President - Drug Discovery
Bio & Compensation  - Reuters
Lilischkis Kimberley Clinical & Regulatory Affairs Manager
Bio & Compensation  - Reuters
Stephen Palmer Program Director - Degenerative Diseases
Bio & Compensation  - Reuters
Justine R. Stehn Ph.D. Director - ATM Program
Bio & Compensation  - Reuters
Bryce Carmine Non-Executive Director
Bio & Compensation  - Reuters
Steven Roy Stent Coffey Non-Executive Director
Bio & Compensation  - Reuters